Literature DB >> 17600274

Spectral karyotyping detects chromosome damage in bronchial cells of smokers and patients with cancer.

Marileila Varella-Garcia1, Lin Chen, Roger L Powell, Fred R Hirsch, Timothy C Kennedy, Robert Keith, York E Miller, John D Mitchell, Wilbur A Franklin.   

Abstract

RATIONALE: Lung cancer is a multistep process that is preceded and often accompanied by molecular cytogenetic lesions in benign bronchial epithelium, the precise character, extent and timing of which are not well defined.
OBJECTIVES: In this study we comprehensively defined molecular cytogenetic changes in bronchial cells that may precede lung carcinoma using spectral karyotyping (SKY).
METHODS: SKY was applied to cultured benign bronchial cells from 43 high-risk smokers without carcinoma, 14 patients with concurrent lung carcinoma, and 14 never-smoker healthy volunteers.
MEASUREMENTS AND MAIN RESULTS: The proportion of cells displaying numeric or structural anomalies/total number of metaphase cells was calculated for each case and was referred to as the chromosomal abnormality index. Mean chromosomal abnormality indices were 15.8, 10.1, and 0.7% for patients with cancer, high-risk smokers, and never-smokers, respectively. Clonal abnormalities were found in 17 (40%) of the high-risk smokers without carcinoma and 7 (50%) of the patients with carcinoma, but in none of 14 (0%) never-smokers. Chromosomal gains observed by SKY were confirmed in interphase cultured cells or paraffin sections of biopsy specimens by fluorescence in situ hybridization in 11 of 13 cases for which appropriate probes were available. In 6 of 57 high-risk patients or those with carcinoma, identical clonal abnormalities were dispersed at multiple bronchial sites and were admixed with nonclonal cells.
CONCLUSIONS: Clonal and single-cell chromosomal abnormalities are frequent in benign bronchial epithelium during lung carcinogenesis, indicating that chromosomal missegregation and other chromosomal rearrangements occur before overt malignancy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17600274      PMCID: PMC1976541          DOI: 10.1164/rccm.200609-1329OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  32 in total

1.  Persistent increase in chromosome instability in lung cancer: possible indirect involvement of p53 inactivation.

Authors:  N Haruki; T Harano; A Masuda; T Kiyono; T Takahashi; Y Tatematsu; S Shimizu; T Mitsudomi; H Konishi; H Osada; Y Fujii; T Takahashi
Journal:  Am J Pathol       Date:  2001-10       Impact factor: 4.307

2.  Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents.

Authors:  P A Bunn; B Helfrich; A F Soriano; W A Franklin; M Varella-Garcia; F R Hirsch; A Baron; C Zeng; D C Chan
Journal:  Clin Cancer Res       Date:  2001-10       Impact factor: 12.531

Review 3.  Genetic instability in epithelial tissues at risk for cancer.

Authors:  W N Hittelman
Journal:  Ann N Y Acad Sci       Date:  2001-12       Impact factor: 5.691

4.  Chromosomal abnormalities in non-small cell lung carcinomas and in bronchial epithelia of high-risk smokers detected by multi-target interphase fluorescence in situ hybridization.

Authors:  Maura Santos Romeo; Irina A Sokolova; Larry E Morrison; Chan Zeng; Anna E Barón; Fred R Hirsch; York E Miller; Wilbur A Franklin; Marileila Varella-Garcia
Journal:  J Mol Diagn       Date:  2003-05       Impact factor: 5.568

5.  Aneuploidy of chromosome 7 can be detected in invasive lung cancer and associated premalignant lesions of the lung by fluorescence in situ hybridisation.

Authors:  N Zojer; G Dekan; J Ackermann; M Fiegl; H Kaufmann; J Drach; H Huber
Journal:  Lung Cancer       Date:  2000-06       Impact factor: 5.705

6.  Distinct patterns of genetic alterations in adenocarcinoma and squamous cell carcinoma of the lung.

Authors:  S M-H Sy; N Wong; T-W Lee; G Tse; T S-K Mok; B Fan; E Pang; P J Johnson; A Yim
Journal:  Eur J Cancer       Date:  2004-05       Impact factor: 9.162

7.  Cancer statistics, 2006.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Taylor Murray; Jiaquan Xu; Carol Smigal; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2006 Mar-Apr       Impact factor: 508.702

Review 8.  Tobacco smoking, harm reduction, and biomarkers.

Authors:  Peter G Shields
Journal:  J Natl Cancer Inst       Date:  2002-10-02       Impact factor: 13.506

9.  Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas.

Authors:  F R Hirsch; M Varella-Garcia; W A Franklin; R Veve; L Chen; B Helfrich; C Zeng; A Baron; P A Bunn
Journal:  Br J Cancer       Date:  2002-05-06       Impact factor: 7.640

10.  Aneuploidy and prognosis of non-small-cell lung cancer: a meta-analysis of published data.

Authors:  D Choma; J P Daurès; X Quantin; J L Pujol
Journal:  Br J Cancer       Date:  2001-07-06       Impact factor: 7.640

View more
  19 in total

1.  Progressive endobronchial premalignancy: marked by original CIN.

Authors:  Christopher D Coldren; York E Miller
Journal:  Am J Respir Crit Care Med       Date:  2011-10-15       Impact factor: 21.405

2.  Genetic stability of bone marrow-derived human mesenchymal stromal cells in the Quantum System.

Authors:  Mark Jones; Marileila Varella-Garcia; Margaret Skokan; Steven Bryce; Jeffrey Schowinsky; Rebecca Peters; Boah Vang; Michelle Brecheisen; Thomas Startz; Nathan Frank; Brian Nankervis
Journal:  Cytotherapy       Date:  2013-08-28       Impact factor: 5.414

3.  A potential probe set of fluorescence in situ hybridization for detection of lung cancer in bronchial brushing specimens.

Authors:  Yi-Zhen Liu; Zhen Wang; Li-Li Fang; Lu Li; Jian Cao; Xin Xu; Ya-Ling Han; Yan Cai; Liang-Xu Wang; Ming-Rong Wang
Journal:  J Cancer Res Clin Oncol       Date:  2012-04-27       Impact factor: 4.553

4.  Detection of disease specific sialoglycoconjugate specific antibodies in bronchoalveolar lavage fluid of non-small cell lung cancer patients.

Authors:  Sangeeta Mehta; Rakhee Chhetra; Radhika Srinivasan; Suresh C Sharma; Digambar Behera; Sujata Ghosh
Journal:  Glycoconj J       Date:  2010-05-16       Impact factor: 2.916

Review 5.  Update in lung cancer 2007.

Authors:  Sarita Dubey; Charles A Powell
Journal:  Am J Respir Crit Care Med       Date:  2008-05-01       Impact factor: 21.405

Review 6.  Biomarkers of risk to develop lung cancer in the new screening era.

Authors:  Thomas Atwater; Pierre P Massion
Journal:  Ann Transl Med       Date:  2016-04

7.  Preneoplasia of lung cancer.

Authors:  Adi F Gazdar; Elisabeth Brambilla
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

8.  The airway epithelium undergoes metabolic reprogramming in individuals at high risk for lung cancer.

Authors:  S M Jamshedur Rahman; Xiangming Ji; Lisa J Zimmerman; Ming Li; Bradford K Harris; Megan D Hoeksema; Irina A Trenary; Yong Zou; Jun Qian; Robbert Jc Slebos; Jennifer Beane; Avrum Spira; Yu Shyr; Rosana Eisenberg; Daniel C Liebler; Jamey D Young; Pierre P Massion
Journal:  JCI Insight       Date:  2016-11-17

9.  Chromosomal aneusomy in bronchial high-grade lesions is associated with invasive lung cancer.

Authors:  Steinn Jonsson; Marileila Varella-Garcia; York E Miller; Holly J Wolf; Tim Byers; Sarah Braudrick; Porntip Kiatsimkul; Marina Lewis; Timothy C Kennedy; Robert L Keith; Johannes Bjornsson; Annette McWilliams; Stephen Lam; Fred R Hirsch; Wilbur A Franklin
Journal:  Am J Respir Crit Care Med       Date:  2007-11-07       Impact factor: 21.405

10.  SH3GL2 is frequently deleted in non-small cell lung cancer and downregulates tumor growth by modulating EGFR signaling.

Authors:  Santanu Dasgupta; Jin Sung Jang; Chunbo Shao; Nitai D Mukhopadhyay; Upneet K Sokhi; Swadesh K Das; Mariana Brait; Conover Talbot; Rex C Yung; Shahnaz Begum; William H Westra; Mohammad Obaidul Hoque; Ping Yang; Joanne E Yi; Stephan Lam; Adi F Gazdar; Paul B Fisher; Jin Jen; David Sidransky
Journal:  J Mol Med (Berl)       Date:  2012-09-12       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.